[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo, AstraZeneca
DS-8201: Acceptance of regulatory submission for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial) in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Acceptance of regulatory submission for HER2-positive/negative unresectable and/or metastatic breast cancer (based on DESTINY-Breast03, DESTINY-Breast04 trial) in 2021 or later 
Regulatory
https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_clinical_trials_appendix.pdf
 
Oct 24, 2019
 
 
9c516b0a-d320-4bb4-81b5-1152c1dba25a.jpg